Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22,492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Banerjee S, et al. Among authors: choi y. Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023. Ann Oncol. 2018. PMID: 29401246 Free article. Clinical Trial.
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Weekes CD, et al. Among authors: choi y. Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693. Epub 2016 Jan 28. Mol Cancer Ther. 2016. PMID: 26823490 Clinical Trial.
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Liu JF, et al. Among authors: choi yj. Ann Oncol. 2016 Nov;27(11):2124-2130. doi: 10.1093/annonc/mdw401. Ann Oncol. 2016. PMID: 27793850 Free article. Clinical Trial.
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd. Gerber DE, et al. Among authors: choi y. Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20. Clin Cancer Res. 2020. PMID: 31540980 Clinical Trial.
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Moore KN, Birrer MJ, Marsters J, Wang Y, Choi Y, Royer-Joo S, Lemahieu V, Armstrong K, Cordova J, Samineni D, Schuth E, Vaze A, Maslyar D, Humke EW, Hamilton EP, Liu JF. Moore KN, et al. Among authors: choi y. Gynecol Oncol. 2020 Sep;158(3):631-639. doi: 10.1016/j.ygyno.2020.05.039. Epub 2020 Jun 11. Gynecol Oncol. 2020. PMID: 32534811 Free article. Clinical Trial.
High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
Guan Y, Mayba O, Sandmann T, Lu S, Choi Y, Darbonne WC, Leveque V, Ryner L, Humke E, Tam NWR, Sujathasarma S, Cheung A, Bourgon R, Lackner MR, Wang Y. Guan Y, et al. Among authors: choi y. J Mol Diagn. 2017 Nov;19(6):921-932. doi: 10.1016/j.jmoldx.2017.08.001. Epub 2017 Sep 1. J Mol Diagn. 2017. PMID: 28867605 Free article.
BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC, Suvada J, Dunkel IJ, Casanova M, Zhang W, Ritchie N, Choi Y, Park J, Das Thakur M, Simko S, Wan Rachel Tam N, Ferrari A. Chisholm JC, et al. Among authors: choi y. Pediatr Blood Cancer. 2018 May;65(5):e26947. doi: 10.1002/pbc.26947. Epub 2018 Jan 19. Pediatr Blood Cancer. 2018. PMID: 29350463 Free PMC article. Clinical Trial.
Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O. Kim D, et al. Among authors: choi y. PLoS One. 2016 Nov 15;11(11):e0165856. doi: 10.1371/journal.pone.0165856. eCollection 2016. PLoS One. 2016. PMID: 27846280 Free PMC article.
22,492 results
You have reached the last available page of results. Please see the User Guide for more information.